Treatment of uncomplicated gonococcal urethritis with cefoxitin: comparison with penicillin
| Autor: | Stuart T. Brown, Sumner E. Thompson, Martin S. Siegel, Gladys H. Reynolds, Clyde Thornsberry, P.L. Perine |
|---|---|
| Rok vydání: | 1979 |
| Předmět: |
Microbiology (medical)
Male medicine.medical_specialty Spectinomycin medicine.drug_class Antibiotics Gonorrhea Penicillins urologic and male genital diseases medicine.disease_cause Cefoxitin Random Allocation Internal medicine polycyclic compounds Medicine Humans Clinical Trials as Topic Penicillin G Procaine business.industry Urethritis medicine.disease Penicillin Infectious Diseases Immunology Neisseria gonorrhoeae business Cefuroxime medicine.drug |
| Zdroj: | Reviews of infectious diseases. 1(1) |
| ISSN: | 0162-0886 |
| Popis: | Cefoxitin is a semisynthetic cephamycin with good in vitro activity against Neisseria gonorrhoeae. In a controlled clinical trial, 143 men with uncomplicated gonococcal urethritis received either cefoxitin (2.0 g intramuscularly [im] with 1.0 g of oral probenecid) or aqueous procaine penicillin G (4.8 X 106 units im with 1.0 g of oral probenecid). Of the 117 patients who returned for follow-up on days 3-13 after treatment, only 1.8% in the group given cefoxitin and 3.6% in the group given penicillin were not cured. The incidence of pain at the site of injection and rates of adverse reactions were similar for both groups. No hematologic, renal, or hepatic toxicity could be ascribed to either treatment regimen. Although none of the infections were due to P-lactamase-producing gonococci, the results provide a basis for additional studies of the efficacy of cefoxitin in treatment of infections due to penicillinase-producing N. gonorrhoeae. With the emergence of penicillinase (8-lactamase)-producing Neisseria gonorrhoeae in 1976, new therapeutic problems have arisen [1, 2]. Although several safe and effective drug regimens have been developed for the treatment of infections due to non-penicillinase-producing gonococci [3, 4], either these drugs (with the exception of spectinomycin) have exhibited prohibitively high rates of failure against penicillinase-producing N. gonorrhoeae or their in vitro activity against the new strains makes their use inadvisable [5]. At present there are no drugs with singlesession regimens recommended by the U.S. Public Health Service for therapy of gonorrhea [6] that might serve as a back-up to spectinomycin should penicillinase-producing N. gonorrhoeae acquire resistance to spectinomycin [5]. Two f/-lactam antibiotics, cefuroxime and cefoxitin, have been mentioned as potentially useful agents in the treatment of infections due to No claim is intended for the utility of cefoxitin in the single-dose therapy of acute, uncomplicated gonorrhea. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|